enVVeno Medical Corporation
NCM: NVNOLive Quote
📈 ZcoreAI Score
Our AI model analyzes enVVeno Medical Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get NVNO Z-Score →About enVVeno Medical Corporation
Healthcare
Medical Devices
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
📊 Fundamental Analysis
enVVeno Medical Corporation demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -56.2%, which indicates that capital utilization is currently under pressure.
At a current price of $11.05, NVNO currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $8.67 - $196.70).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$7.24M
Trailing P/E
--
Forward P/E
-9.29
Beta (5Y)
1.09
52W High
$196.70
52W Low
$8.67
Avg Volume
22K
Day High
Day Low